GLP-1 weight-loss plateau: how to review the plan

A question posted this week asked what to do when weight loss slows after a long period on a GLP-1. Feeling stuck is understandable, but the scale alone cannot establish that treatment has failed. The useful next step is to review the trajectory, goals, effects and safety with a clinician — without changing the dose or product on your own.

A plateau can be part of a treatment trajectory and does not automatically mean a GLP-1 has stopped working. A clinical review can look at the trend, health goals, tolerability and safe options before anything changes. (Read more)

A plateau is a trend, not a verdict

Weight loss is often faster early in treatment and then slows over time. A single change on the scale does not define a plateau; a clinician will look for a persistent trend measured under comparable conditions. The review also distinguishes slowing after an initial response, limited response from the start and a gap between expected results and what treatment can reasonably provide. Those situations do not all lead to the same decision.

Look beyond the number on the scale

Obesity Canada recommends personalized goals that include health and outcomes that matter to the individual. A review may therefore consider changes in weight-related health complications, mobility, sleep, hunger, cravings, quality of life and the ability to maintain realistic health behaviours. This broader view avoids treating one number as the only measure of success and helps keep the conversation free of weight stigma.

What a clinician may review with you

Bring the treatment timeline, the doses actually prescribed and used, interruptions, side effects, other medications, recent health changes and a weight trend gathered under comparable conditions. A clinician may also ask whether hunger or cravings have changed and whether the current plan remains workable. This review helps clarify the context; it does not by itself confirm a cause or make a higher dose, product switch or prescription automatic.

Do not change treatment on your own

Obesity Canada describes pharmacotherapy as a long-term strategy when it is effective and tolerated, used with health-behaviour changes. Dosing is individualized around goals, benefit and tolerability; not everyone needs the maximum dose. Changing or discontinuing treatment can also have consequences, including weight regain. Decisions to continue, adjust, replace or discontinue medication belong in a discussion with the prescriber.

When a weight-management consultation may fit

If progress has slowed, treatment effects feel different or goals need to be reassessed, MedVibe’s weight-management service lets you present your history and questions to a clinician. The evaluation determines whether virtual care fits and which next steps are reasonable. A particular medication, dose change, prescription and outcome are never automatic, and in-person assessment may be recommended.

This guide is general information and does not replace an individual assessment. Responses to GLP-1 medications vary, and other health conditions or medicines may affect weight, appetite or tolerability. Do not use a social post to change treatment. For a non-urgent health question in Quebec or Ontario, call 811. For severe symptoms, rapid deterioration or an emergency, call 911 or go to an emergency department.